Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas
Founded by world-renowned scientist Feng Zhang, Ph.D., of the Broad Institute of MIT and Harvard, and joined by a distinguished set of industry leaders and company builders
$193 million raised from leading life sciences investors ARCH Venture Partners, GV and Lux Capital
BOSTON–(BUSINESS WIRE)–Aera Therapeutics announced its launch today with a vision to harness its proprietary delivery platform to unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas. Aera’s delivery platform is based on research conducted in the laboratory of scientific founder Feng Zhang, Ph.D., core member of the Broad Institute of MIT and Harvard, McGovern Institute investigator, the James and Patricia Poitras Professor of Neuroscience at MIT and an investigator at the Howard Hughes Medical Institute, and is designed to address the limitations of today’s delivery technologies in order to more broadly enable new genetic medicines. The company has raised $193 million in combined Series A and B financings led by ARCH Venture Partners, GV and Lux Capital.
“Genetic medicines—comprising both a payload and a delivery system—are powerful modalities with wide-ranging therapeutic applications for the treatment of human disease; however, the advancement of delivery technologies has lagged the rapid evolution of payload technologies, limiting the broad application of genetic medicines,” said Akin Akinc, Ph.D., chief executive officer of Aera. “Challenges remain with current delivery approaches, and genetic medicines applications have been generally restricted to the liver and ex vivo settings. Aera’s goal is to change this. With access to enabling delivery and payload technology, we aim to expand the reach of genetic medicines to different tissues and applications to benefit more patients across more disease areas.”
Enabling New Genetic Medicines
Aera’s proprietary protein nanoparticle (PNP) genetic medicine delivery platform leverages the discovery of endogenous, human proteins derived from retroelements that can self-assemble to form capsid-like structures and which can package and transfer nucleic acid cargo. This platform combines the benefits of an endogenous, self-assembling system with the engineerability of a protein-based system and has the potential to enable the delivery of various genetic medicine modalities.
Aera’s technology also includes a licensed therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene editing enzymes. The compact size of these enzymes may help overcome the packaging and delivery challenges of current gene editor systems.
Aera’s founding leadership and board of directors includes:
Akin Akinc, Ph.D., chief executive officer and board member
John Maraganore, Ph.D., board chair and former founding chief executive officer, Alnylam
Robert Nelsen, board member and managing director, ARCH Venture Partners
Issi Rozen, board observer and venture partner, GV
Vicki Sato, Ph.D., board member and former president, Vertex Pharmaceuticals
David Schenkein, M.D., board member and general partner, GV
Josh Wolfe, board member and co-founder and managing partner, Lux Capital
“We have long understood the potential of genetic medicines—which includes modalities such as RNAi, mRNA, gene therapy and gene editing—to revolutionize the way we treat disease. However, delivery challenges remain, and have yet to be overcome to realize the full promise of these potentially transformative therapies,” said John Maraganore, Ph.D., board chair of Aera. “Aera’s endogenous human PNP platform represents an exciting new approach for the delivery of genetic medicines. I am thrilled to work alongside this exceptional team and to be a part of Aera’s journey.”
Aera Therapeutics is a biotechnology company leveraging its proprietary protein nanoparticle (PNP) delivery platform to unlock the full potential of genetic medicines. Aera’s platform, based on endogenous human proteins, is being developed to address the limitations of today’s delivery technologies and to expand the reach of genetic medicines to different tissues and applications, in order to benefit more patients across more disease areas. Aera’s licensed technology also includes a therapeutic enzyme platform based on the discovery of novel, compact and programmable gene editing enzymes. Aera is headquartered in Boston and has raised $193 million to date from leading life sciences investors. To learn more, please visit www.aeratx.com and follow us on LinkedIn.